Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 27, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Placebo for risankizumab Clear all

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab IV, placebo for risankizumab, risankizumab SC; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 82
States / cities: Coronado, California • Irvine, California • La Jolla, California + 63 more

Conditions: Crohn's Disease
Interventions: placebo for risankizumab, risankizumab IV, risankizumab SC; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 931 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 117
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more

Conditions: Psoriasis
Interventions: Risankizumab, Placebo solution for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more

Conditions: Crohn's Disease, Inflammatory Bowel Diseases
Interventions: Fluconazole, Placebo, IL-23 Therapy; Drug · Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: placebo for risankizumab IV, risankizumab SC, risankizumab IV; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 114
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more

Conditions: Asthma
Interventions: placebo, risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 20
States / cities: Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more

Conditions: COVID-19
Interventions: Placebo, Remdesivir, Risankizumab; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more

Conditions: Dermatitis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more

Conditions: Crohn's Disease
Interventions: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 111
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Conditions: Psoriatic Arthritis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more

Conditions: Genital Psoriasis, Scalp Psoriasis
Interventions: Risankizumab, Placebo for Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Hidradenitis Suppurativa
Interventions: Risankizumab, Placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Hot Springs, Arkansas • Bakersfield, California • Los Angeles, California + 17 more

Conditions: Psoriatic Arthritis (PsA)
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 55
States / cities: Anniston, Alabama • Fullerton, California • Huntington Beach, California + 50 more

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab, placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 78
States / cities: Coronado, California • Irvine, California • La Jolla, California + 60 more

Conditions: Crohn's Disease
Interventions: Risankizumab SC, Placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 79
States / cities: Sun City, Arizona • Corona, California • Coronado, California + 65 more

Search by objective public record fields.

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.